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Abstract
Background: Glioblastoma (GBM) develops resistance to the advances in chemotherapy leading to poor prognosis
and life quality. Consequently, new treatment modalities are needed. Our aims were to investigate the effects of
combined noscapine (NOS) and imatinib mesylate (IM) on human GBM in vitro and the role of midkine (MK) in this
new combination treatment.
Methods: Monolayer and spheroid cultures of T98G human GBM cell line were used to evaluate the effects of IM
(10 μM), Nos (10 μM) and their combination on cell proliferation and apoptotic indexes, cell cycle, the levels of
antiapoptotic MK, MRP-1, p170, PFGFR-a, EGFR, bcl-2 proteins, apoptotic caspase-3 levels, morphology (SEM) and
ultrastructure (TEM) for 72 hrs. Results were statistically analyzed using the Student’s t-test.
Results: The combination group induced highest decrease in cell proliferation and apoptotic indexes, caspase-3
levels, MRP-1 and PDGFR-a levels. The decrease in p170 levels were lower than IM but higher that NOS. The
highest increases were in EGFR, MK, bcl-2 and cAMP levels in the combination group. The G0+G1 cell cycle arrest
at the end of 72
nd hr was the lowest in the combination group. Apoptotic appearence was observed rarely both in
the morphologic and ultrastructural evaluation of the combination group. In addition, autophagic vacuoles which
were frequently observed in the IM group were observed rarely.
Conclusions: The combination of Nos with IM showed antagonist effect in T98G human GBM cells in vitro. This
antagonist effect was correlated highly with MK levels. The effects of NOS on MRP-1, MK and receptor tyrosine
kinase levels were firstly demonstrated in our report. In addition, we proposed that MK is one of the modulator in
the switch of autophagy to cell death or survival/resistance.
Background
Glioblastoma (GBM) is the most common and malig-
nant primary brain tumor. Although various combined
therapies of surgery, radiation and chemotherapy are
tried in order to cope with resistance and relapse to
prolong survival time, the prognosis of patients remains
poor. The majority of the patients die within a year of
diagnosis and the five-year-survival of patients world-
wide with glioma is only 10% [1].
In the chemotherapy era, this shortcoming leads
investigators to design new antineoplastic agents and to
use them alone or in combination with previously-used
agents. Although these advances achieved some success,
this process from bench to in vivo and phase trials took
considerable time and financial resources, resulting in
more deaths. Consequently, investigators started to
search whether or not, commonly and effectively used
non-antineoplastic drugs long-used in clinic had anti-
neoplastic effects and/or ability to potentiate antineo-
plastic drug cytotoxicity [2,3]. A plant alkaloid with
well-known antitussive effects Noscapine (Nos) was
investigated in these trials and Nos was proposed as a
promising antineoplastic agent. The anticancer action of
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attenuation of microtubule dynamics through activation
of mitotic checkpoints. It has been shown that Nos
binds stoichiometrically to tubulin and then promotes
microtubule polymerization but does not alter the
steady state monomer/polymer ratio of tubulin, and
consequently causes growth arrest of tumor cells during
mitosis, and also reverses P-gp mediated drug resistance
[4,5]. In addition, researchers chose to investigate cur-
rent antineoplastic agents when their success was pro-
ven for specific cancer types or for other cancer types.
These antineoplastic agents target the same pathways
but are often affected negatively by different mutations
such as IM in chronic myeloid leukemia and GBM
treatments [6,7].
IM is a tyrosine kinase inhibitor as a platelet-derived
growth factor receptor (PDGFR) interacting with the
adenosine triphosphate (ATP)-binding site. IM was
initially designed to treat chronic myelogenous leuke-
mia but the success of this compound in this treat-
ment led to broader application in the treatment of
other tumors, such as gastrointestinal tumours, ana-
plastic thyroid cancer, prostate cancer and gliomas
[6-10]. Previous reports demonstrated that monother-
apy by using IM is efficacious in in vitro models of
GBM because of its potency to inhibit the signaling
pathway of PDGFR [11]. Although it was shown that
monotherapy with IM is also effective in in vitro mod-
els of GBM, IM could not achieve the same success as
in in vivo models because of its poor brain distribution
[12]. Unfortunately, in accordance with in vivo studies,
monotherapy with IM has minimal activity in Phase II
studies of GBM. IM did not show the dramatic results
that are sometimes seen with other targeted therapies
such as IM in CML [13]. The reason explained by pre-
vious studies was that IM is a substrate of two efflux
pumps P-glycoprotein (P-gp) and breast cancer resis-
tance protein (BCRP1) which are excreted by the drug
from the cell and expressed at the blood-brain barrier
(BBB) [13,14].
Midkine (MK), a heparin-binding growth factor, was
originally reported to be the product of a retinoic acid-
responsive gene during embryogenesis [15]. Its expres-
sion is high during embryogenesis, but interestingly, MK
is undetectable in healthy adults and only reappears in
the body as a part of disease pathogenesis. Moreover,
the most intriguing feature of MK is its high-frequency
and massive expression in advanced tumors [16-19].
Previous reports showed that increased levels of MK
expression correlate with the progression of human
astrocytomas, MK mRNA and protein expression levels
were higher in high-grade astrocytomas (anaplastic
astrocytomas and GBMs) than in low-grade astrocyto-
mas [20].
Previous reports showed that Nos led to a potent inhi-
bition of cell proliferation and induced apoptosis in
glioma/GBM cell lines in vitro and in vivo [21,22]. In
addition it was shown that Nos reversed P-gp induced
resistance through c-jun-NH2-terminal kinase (JNK) in
human gastric and pancreatic carcinomas [5]. In the
present study, we investigated primarily whether Nos
could potentiate the cyctotoxicity of IM in human GBM
cells in vitro and secondly we also investigated the role
of MK as a survival and resistance molecule in this
combination treatment. We thought MK can involve in
the fate of this new combination chemotherapy.
Methods
Monolayer and spheroid cell cultures
T98G human GBM cell line was provided by the Ameri-
can Type Culture Collection (ATCC; Rockville, USA)
and was grown in monolayer culture in Dulbecco’s
Modified Eagle’s Medium-F12 (DMEM-F12; Biological
Industries, Israel) supplemented with 10% heat-inacti-
vated foetal calf serum, 1 mM sodium pyruvate, 0.1 mM
non-essential aminoacid solution, 50 units/ml penicillin
and streptomycin (Sigma Chemical Co., St Louis, Mis-
souri). Cells in semiconfluent flasks were harvested
using 0.05% trypsin, 0.53 mM EDTA solution (Sigma
Chemical Co., St Louis, Missouri) and centrifuged after
the addition of DMEM-F12 for trypsin inactivation and
then resuspended in culture medium. Following trypan
blue exclusion assay, GBM cells were plated in six-well
culture plates containing 5 ml DMEM-F12 medium at a
concentration of 5 × 10
5 cells/well with 100% vitality.
An in vitro multicellular T98G GBM spheroid model
was established using a liquidoverlay technique. Briefly,
semi-confluent monolayer cell cultures were trypsinized
and single cells with 100% vitality were cultured over
3% Noble agar-coated (Difco, USA) six-well culture
plates containing 5 ml DMEM-F12medium at a concen-
tration of 1 × 10
6 cells/well.
Experimental design
I Ma n dN o sw e r ea p p l i e da tav o l u m eo f1 0 0μlt o
monolayer cultures of T98G GBM cells in concentra-
tions ranging from 1 μMt o2 0 0μM, while the negative
control cells received only nutrient medium alone. Cul-
tures were incubated with drugs for 72 hrs. The inhibi-
tion concentration 50 (IC50) values were determined as
10 μM for two drugs. Experiments were performed in
monolayer and spheroid cultures of T98G human GBM
cells. Groups were identified as control, IM (10 μM),
Nos (10 μM) and their combination. For every experi-
mental group n = 6. All experiments were repeated
three times and achieved similar results. Cell prolifera-
tion index (total cell number by propidium iodide (PI)
staining), apoptotic index by flow cytometric (FCM)
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FITC/PI) staining, cell cycle by (FCM), the levels of cas-
pase-3, MK, epidermal growth factor receptor (EGFR)
by enzyme-linked immunosorbent assay (ELISA), the
levels of bcl-2, multi-dug resistance protein-1 (MRP-1),
p170, PDGFR alpha (PDGFR-a) by Western blotting,
cAMP levels by radioimmunoassay (RIA), morphology
by scanning electron microscopy (SEM) were evaluated
in monolayer cultures for 72 hrs. In addition, cell ultra-
structure was evaluated in spheroid cultures by using
transmission electron microscopy (TEM) for 24 hrs.
Cell proliferation index
The total cell number was counted by using an auto-
mated cell counter (nucleocounter, Denmark). The star-
ter kit which is compatible to cell counter and includes
lysis buffer, stabilization buffer, nucleocasettes and soft-
ware was used. Cells were harvested every 24 hrs for 72
hrs. Cells were pre-treated with lysis and stabilization
buffers to dissolve cell aggregates and lyse cell mem-
branes. Pre-treated cells were loaded to nucleocasettes
which were coated with propidium iodide (PI) dye and
their nuclei were stained with PI. Nucleocasettes were
placed in device for 30-35 seconds to measure the PI
fluorescence and then cell counts were analyzed with
the software and recorded.
Apoptotic index
One of the manifestations of apoptosis is the transloca-
tion of phosphotidylserine (PS) from the inner mem-
brane to the outer side of the plasma membrane.
Externalization of PS was studied by the Annexin-V-
binding assay. Briefly, cells were washed twice with PBS
and resuspended by binding buffer containing 0.01 M
H E P E S ,0 . 1 4m MN a C la n d2 . 5m MC a C l 2. A cell sus-
pension (1 × 10
5 cells in 100 μl) in binding buffer was
incubated with 5 μl of FITC-labeled Annexin V (BD
Pharmingen, San Diego, CA, USA) dye and propidium
iodide (PI) for 15 mins in the dark at room temperature.
After incubation, the PI fluorescence and Annexin V
were measured simultaneously in a BD FACS Calibur
a n da n a l y z e dw i t ht h ei n s t r u m e n t ’s operating software
(CellQuest: BD Pharmingen, San Diego, CA, USA). Data
acquisition and analysis were undertaken with CellQuest
and WinMDI programs.
Caspase-3 levels
Cell culture supernatants were analyzed for caspase-3
levels in triplicate, using fluorimetric kits (Sigma
Aldrich, Missouri, USA). The caspase-3 fluorimetric
assay is based on the hydrolysis of the peptide substrate
acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin
(Ac-DEVD-AMC) by caspase 3, resulting in the release
of the fluorescent 7-amino-4-methylcoumarin (AMC)
moiety. 1 × 10
4 cells seeded in each well of 96 well
plates washed twice in PBS and incubated in CHAPS
lysis buffer at 4°C for 20 mins. 5 μl cell lysate was trans-
fered into the wells of other 96 well plates then incu-
bated with 5 μl of 2 mM Ac-DEVD-pNA peptide
substrate and 200 μl of assay buffer (HEPES 20 mM, pH
7.4, CHAPS 0.1%, DTT 5 mM, EDTA 2 mM) at 37°C
for 1 hr in an incubator. The concentration of AMC
released was quantified by reading in a fluorometer with
a 360 nm excitation filter and 460 nm emission filter for
optimal sensitivity.
Cell cycle
The effects of drugs on the cell cycle were examined
using a DNA analysis kit (BD Pharmingen, San Diego,
CA, USA) according to the manufacturer’s instructions.
Briefly, T98G GBM cells were induced at a cell density
of 5 × 10
5 cells/ml in the presence of each drug applied
separately and in combination for different time inter-
vals (24 and 72 hrs). Cells were then harvested, centri-
fuged, washed and resuspended in buffer
(dimethylsulfoxide in sucrose-sodium citrate) for 5 mins
at room temperature. A mixtur eo ft r y p s i ni ns p e r m i n e
tetrahydrochloride detergent buffer was added and sam-
ples were incubated for 20 mins at room temperature.
After the addition of RNase A and trypsin inhibitor in
spermine buffer, cells were incubated with propidium
iodide, in dark, for 20 mins at 4°C. Finally, flow cyto-
metric analysis was performed immediately using a Facs-
can flow cytometer (FACS Diva, Beckman-Dickinson,
California, USA) and fluorescence intensity data were
acquired using the instrument’s operating software
(CellQuest: BD Pharmingen, San Diego, CA, USA). The
percentages of the analyzed cell population in G0/G1-,
S-, or G2/M-phases were determined by the Mod Fit
cell-cycle analysis program.
MK levels
Cell culture supernatants were analyzed for MK levels in
triplicate, using ELISA kits (Peprotech). The lower
detection limit of the assay was 150 pg/ml for MK. MK
levels were measured by an ELISA system in which
polyclonal antihuman MK was used as capture antibody
(Peprotech). Detection was bybiotinylated polyclonal
antihuman MK antibody (Peprotech) followed by strep-
tavidin HRP (Sigma) and a TMB enzyme substrate sys-
tem (Sigma). The reaction was stopped by 1 M H2SO4
a n dr e a d i n g sw e r em a d ea t4 5 0n mb yas p e c t r o m e t e r
(M2, Molecular devices, CA, USA).
cAMP levels
Following centrifugation, the supernatant was removed
and 0.1 N HCl with DMEM-F12 medium (1:1) was
added to cells to stop the reaction at each 24 hrs
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sure cAMP levels. cAMP accumulation was measured in
the supernatants according to the method previously
described with some modifications [23]. cAMP was
determined by RIA using the acetylation protocol. High-
affinity rabbit anti-cAMP antibodies were raised in our
laboratory using BSA-conjugated cAMP. Succinyl-cAMP
tyrosine methylester (ScAMP-TME) was iodinated by
the chloramine-T method. Mono- and diiodo ScAMP-
TME were used as tracer ligands for the radioimmu-
noassay (RIA) and then purified by gel-filtration chro-
matography (Sephadex G25 superfine), equilibrated and
eluted with 1 M sodium acetate (pH:5).
EGFR levels
Cell culture supernatants were analyzed for EGFR
levels in triplicate, using ELISA kits (SABiosciences,
Germany). EGFR levels were measured by an ELISA
system in which antihuman EGFR was used as capture
antibody (SABiosciences, Germany) and detection was
by biotinylated polyclonal antihuman EGFR antibody
(SABiosciences) followed by streptavidin HRP (SABios-
ciences, Germany) and a TMB enzyme substrate sys-
tem (SABiosciences, Germany). The reaction was
stopped by 2 M H2SO4 and readings were made at 450
nm by a spectrometer (M2, Molecular devices, CA,
USA).
PDGFR-a, MRP-1, Bcl-2 and p170 levels by western
blotting
Expression of PDGFR-a,M R P - 1 ,B c l - 2 ,p 1 7 0p r o t e i n s
were detected by Western blot analysisas described in
previous reports. 2 × 10
6 cells were lysed for 15 mins
at 4°C in RIPA lysis buffer. Protein content was
assessed using BCA protein assay (Pierce, Rockford,
USA). Samples with equal amounts of protein were
separated on a 7 and 10% sodium dodecyl sulfate poly-
acrylamide gelelectrophoresis (SDS-PAGE) gel, trans-
ferred to polyvinylidene fluoride (PVDF) membranes
detected with PDGFR-a, MRP-1, bcl-2, p170 1/100
dilution and all from Santa Cruz Biotechnology, CA,
USA and b-actin (1/1000 dilution, Pierce, Rockford,
USA) antibodies. Protein bands were visualized with
the enhanced chemiluminescence (ECL) Advance Wes-
tern blot detection reagents (GE Healthcare Life
Sciences, NJ, USA) and quantified by the ImageJ image
processing program (National Institutes of Health,
Bethesda, MD).
Morphology by SEM
T98G GBM cells were seeded on microslides in 24-well
culture plates containing 1 ml of DMEM-F12 medium
at a concentration of 5 × 10
4 cells/well. After cell
attachment, drugs at a concentration of 10 μMw e r e
applied to the cell cultures individually and in combina-
tion. Cells were fixed with 2.5% glutaraldehyde in 0.1 M
of sodium cacodylate buffer (pH: 7.4) for 1 hr at 4°C.
Cells were washed twice for 10 mins with 0.1 M of
sodium cacodylate buffer and post-fixed in 1% osmium
tetraoxide for 1 hr at 4°C. The cells were dehydrated in
a graded acetone series and incubated in amyl acetate.
Microslides were critical-point dried, sputter coated
with gold-palladium and observed by SEM (Jeol-JSM-
5200). Photographs were taken at several magnifications.
Ultrastructure by TEM
Harvested spheroids were fixed with 2.5% glutaralde-
hyde in 0.1 M sodium cacodylate buffer and post-fixed
in 1% osmium tetraoxide in 0.1 M sodium cacodylate
buffer for 1 hr at 4°C. Cells were incubatedin 1% uranyl
acetate for 1 hr at 4°C, dehydrated in a graded acetone
series and embedded in Epon 812. Samples were cut
using a rotating blade microtome (Leica, Heerbrugg,
Switzerland) and 70 nm-thick sections were mounted
on copper grids. Sections were subsequently stained
with 5% uranyl acetate and counterstained with Rey-
nold’s lead citrate. Sections were examined with a Jeol-
Jem 1011 TEM. Photographs were taken at several
magnifications.
Statistical analysis and determination of synergism
SPPS 17.0 statistical software (SPSS, Inc., Chicago, IL,
USA) was used for the statistical analysis. All the
results were statistically analyzed using the Student’s
t-test. Data were represented as mean ± standard error
mean (SEM). p<0.05 was considered significant.
Synergy was determined as described previously
[24-26]. Briefly, synergism was determined using the
following formula: Combination index (CI): D1/(DX)1+
D2/(DX)2, where D1 is tested concentration of IM
used in combination with Nos, D2 is the tested con-
centration of Nos used in combination with IM, (DX)1
i st h ec o n c e n t r a t i o no fas i n g l ya p p l i e dI Ma n d( D X ) 2
is the concentration of a singly applied Nos. A CI
value of 1 indicates an additive effect, a CI value < 1
indicates a synergistic effect and a CI value > 1 indi-
cates an antagonist effect.
Results
Cell proliferation index
The effects of drug applications are summarized in
Figure 1. The cell number of the control group showed
a proportional increase as a function of incubation time
up to 72 hrs. All drug treatments inhibit cell prolifera-
tion of T98G GBM cell lines for 72 hrs (p < 0.05) in a
time-dependent manner. The highest decrease was
determined at IM, Nos and the combination group,
respectively (p < 0.05).
Erguven et al. Cancer Cell International 2011, 11:18
http://www.cancerci.com/content/11/1/18
Page 4 of 11Apoptotic index and caspase-3 levels
Figure 2 clearly shows different levels of apoptosis
(Figure 2A) and caspase-3 activity (Figure 2B) induced
by these drug applications. Nos, IM and the combina-
tion group increased apoptosis and caspase-3 activity at
the 24
th hr and the 72
nd hr (p < 0.05). IM was the
potent apoptosis inducer among other drug applications
and the latter was Nos (p < 0.05).
Cell cycle
T98G GBM cells demonstrated growth arrest at the S-
phase within 24 h of drug treatments but they demon-
strated G0+G1 arrest at the 72
nd hr. IM was the most
potent drug to induce S-phase arrest at the 24
th hr and
Nos was apotent G0+G1 phase arrest inducer at the
72
nd hr (p < 0.05) (Figure 3).
MK levels
The alterations in MK levels for 72 hrs are summarized
in Figure 4. All drugs alone and incombination
decreased MK levels at the 24
th hr, However, only IM
and Nos decreased these levels at the 72
nd hr (p < 0.05).
The combination group increased these levels at the
72
nd hr (p < 0.05).
cAMP levels
cAMP levels were measured to assess the metabolic
activity, growth and survival of cells. The cAMP level of
the untreated control group culture increased from cul-
ture time zero to 72 hrs (p < 0.05)(Figure 5). The drug
treatments reduced cAMP levels both individually and
in combination (p < 0.05). The highest decrease was
Figure 1 Cell proliferation index. Nos, noscapine; IM, imatinib
mesylate; Nos+IM, noscapine with imatinib mesylate. Results are
mean of three different experiments and are presented as mean ±
standard error mean (SEM).
Figure 2 Apoptotic index.( A)The panels of flow cytometric analysis of apoptotic index. According to kits’ instruction manual, quadrants of
panels were defined as: the lower left quadrant of density plots for the numbers of viable cells (annexin V-; PI-), the lower right quadrant for the
numbers of earlier stages of apoptotic cells (annexin V+; PI-), the upper right quadrant for the numbers of late stages of apoptotic cells (annexin
V+; PI+), and the upper left quadrant for the numbers of dead cells. In the graph only the percentage of apoptotic cells (lower left and upper
left) were presented. (B) The graph of apoptotic index. The columns in the graph represent the sum of earlier and late stages of apoptotic cells.
(C) The graph of caspase-3 levels. Nos, noscapine; IM, imatinib mesylate; Nos+IM, noscapine with imatinib mesylate. Results are the mean of
three different experiments and presented as mean ± SEM.
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respectively (p < 0.05).
EGFR levels
EGFR levels of control group were almost the same with
Nos group (p > 0.05) at the 24
th hr. IM induced much
higher inhibition than Nos(p < 0.05) and the combina-
tion group led to little increase at the 24
th hr (Figure 6).
EGFR levels for Nos and IM were similar (p > 0.05) and
they led to a sharp decrease at the 72
nd hr (p < 0.05).
EGFR levels of the combination group were almost the
same with the control group (p > 0.05).
PDGFR-a, MRP-1, Bcl-2 and p170 levels by western
blotting
All drugs alone and in combination decreased PDGFR
levels, MRP-1 levels and bcl-2 levels (p < 0.05) (Figure
7). The combination group was very potent in decreas-
ing PDGFR and MRP-1 (p < 0.05), the latter was IM (p
< 0.05). Bcl-2 levels were decreased potently by IM, Nos
and the combination group, respectively (p < 0.05).
Morphology
The control group of C6 glioma cells had a spindle-
shaped appearance and frequent, active mitotic division
phase was observed under SEM (Figure 8A). IM led to a
sharp decrease in the number of microvilli and many
cells changed to possess a globular appearance like a
ball. Apoptotic appearence like grape grains was
fequently observed (Figure 8B). In the Nos group many
cells possessed a wide body with an angular morphology
and a protruding surface because of cell surface knobs
and apoptotic appearence was also observed (Figure 8C).
In the combination group, two different cell types were
observed as follows: i) a wide body with an angular mor-
phology and a protruding surface, ii) a wide body with s
spindle-shaped morphology. Mitotic cell appearence was
also observed in this group (Figure 8D).
Ultrastructure
The control group exhibited normal morphology, char-
acterized by fine-textured nuclear chromatin, intact
nuclear membrane, tubular structured mitochondria,
intact cytoplasmic membrane and many microvilli
which were in contact with other cells under TEM
Figure 3 Cell cycle. The percentage of cells at G0/G1-, S- and G2/
M-phases are plotted (%). Nos, noscapine; IM, imatinib mesylate;
Nos+IM, noscapine with imatinib mesylate. Results are the mean of
three different experiments and presented as mean ± SEM.
Figure 4 Midkine levels. Nos, noscapine; IM, imatinib mesylate;
Nos+IM, noscapine with imatinib mesylate. Results are mean of
three different experiments and presented as mean ± SEM.
Figure 5 cAMP levels. Nos, noscapine; IM, imatinib mesylate; Nos
+IM, noscapine with imatinib mesylate. Results are mean of three
different experiments and presented as mean ± SEM.
Figure 6 EGFR levels. Nos, noscapine; IM, imatinib mesylate; Nos
+IM, noscapine with imatinib mesylate. Results are the mean of
three different experiments and presented as mean ± SEM.
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villi and cell-to-cell connections, thus the integrity of
spheroids was disrupted. This treatment group also
exhibited severe mitochondrial damage, foamy-vacuo-
lated cytoplasm, many presumably autophagic vacuoles
and lytic changes. Apoptotic appearence was frequently
seen in this group (Figure 9B). Nos led to severe mito-
chondria damage and expansion at endoplasmic
reticulum. No autophagic vacuoles were observed. Apo-
totic appearence was oftenly observed in this group (Fig-
ure 9C). The combination group exhibited presumably
autophagic vacuoles which were lower than the IM
group, mild mitochondria damage but healthy mito-
chondria was frequently observed and interestingly
many lipid droplets in several sizes. The apoptotic
appearence was rarely observed (Figure 9D).
Figure 7 PDGFR-a,M R P - 1 ,B c l - 2a n dp 1 7 0l e v e l sb yw e s t e r nb l o t t i n g . Nos, noscapine; IM, imatinib mesylate; Nos+IM, noscapine with
imatinib mesylate. Results are presented as mean (%) ± SEM. Mean values for each group were calculated as the ratio of the density of the
sample band to that of the b-actin band in each lane and multipled with 100 and they are the mean of three different experiments.
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In the present study, we used the combination of Nos
and IM in order to potentiate cytotoxicity in monolayer
cultured and spheroid cultures of human T98G GBM
cells. The combination group showed antagonist effect
leading to high cell proliferation index and low apopto-
tic index. IM was the most effective drug to inhibit cell
proliferation and the latter was Nos.
Previous reports showed the inhibitory effect of Nos
on GBM in vivo and in vitro [21,22]. One of them
which was reported by Newcomb et al. demonstrated
that Nos with IC50 value as 97 μmol/l inhibited T98G
cell proliferation index in 24 hrs, induced M-phase
arrest and led to a maximal cell death within 48 hrs
[22]. In the present study, the maximal cell death was
determined at the 24
th hr by using Nos with the IC50 of
10 μM. In addition, Nos induced S-phase arrest at the
24
th hr and G0+G1 arrest at the 72
nd hr (p < 0.05). Nos
decreased EGFR, PDGFR-a levels and MRP-1 levels.
According our pubmed search, the inhibitory effect of
Nos on tyrosine kinase receptors (TKR) and MRP-1
hasn’t reported yet.
The combination group induced highest decrease in
cell proliferation and apoptotic indexes, caspase-3 levels,
MRP-1 and PDGFR-a levels. The decrease in p170
levels were lower than IM but higher that NOS. The
highest increase in EGFR, MK, bcl-2 and cAMP levels
were determined in the combination group. The G0+G1
cell cycle arrest was the lowest in the combination
g r o u pa tt h ee n do ft h e7 2
nd hr. The apoptotic appear-
ence was rarely observed in morphological and ultra-
structural evaluation. In addition, autophagic vacuoles
were lower than the IM group. The underlying mechan-
ism of antagonism seemed to occur because the combi-
nation group was unable to decrease anti-apoptotic
proteins as EGFR, MK, bcl-2 and in addition it
decreased G0+G1 cell cycle arrest and cytotoxic autop-
hagy of IM. Consequently, the apoptotic index was
decreased.
Phase I-II studies showed that IM is not active in
GBM as they expected due to due to the fact that (1) a
targeted agent was used in an unselected population
which had receptor tyrosine kinase mutations and/or (2)
a targeted agent was blocked by drug efflux proteins as
commonly pronounced P-gp and MRP [27-29]. Previous
studies showed that the inhibition of drug-efflux trans-
porters enhanced cytotoxicity of several antineoplastic
agents as a result of penetration improvement and drug
distribution increase to the nervous system [29]. The
highest decrease by the combination group was
Figure 8 Scanning electron microscopic views of T98 GBM cells at the 24
th hr. (A) The control group (original magnification, ×1.5 k). Thick
Arrow (➜) indicates healthy cell with thin and long body. Apoptotic appearence of T98G cell were shown in a small micrograph. (B) The IM
group (original magnification of big and small electron micrographs are ×2.5 k and ×2.25 k, respectively). Thin arrow (®) indicates peaky and
long microvillus of the cell. Y*, round cell which lost microvillus; Y: round cell with microvillus.(C) The Nos group. Two arrows represent cells
which possess extended and angular body with protruding surface. AP, apoptotic appearence (original magnification, ×3.0 k). (D) The
combination group (original magnification, ×1.80 k). Thick Arrow (➜) indicates healthy cell with thin and long body. Thin arrow (®) indicates
peaky and long microvillus of the cell. Two arrows represent cells which possess extended and angular body with protruding surface. S, cell with
extended body without a shape.
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wasn’t effective in the inhibition of P-gp levels, however
Spiegl-Kreinecker et al. found that a considerable
expression of P-gp was relatively rare in glioma cells, in
contrast to MRP-1 which was constitutively overex-
pressed in cells derived from astrocytomas as well as
GBMs as T98G and SW1088 cells [29]. In the present
study, the inhibition of MRP-1 and P-gp was not
enough to potentiate the cytotoxicity Mukai et al. also
showed that IM is not a substrate for MRP-1 and IM
didn’t have ability to inhibit MRP-1 in leukemia cells. In
addition, they proposed that IM would not enhance
cytotoxicity in MRP-1 overexpressed cells when used in
combination [30]. IM took second place to decrease
MRP-1 levels and in the light of our results, we can pro-
pose that IM would enhance cytotoxicity in MRP-1
overexpressed cells.
Apoptotic appearence was observed rarely both in the
morphologic and ultrastructural evaluation of the com-
bination group. The autophagic vacuoles were frequently
observed in the IM group. Autophagic vacuoles can be
presumed as the first step of cell death because of high
apoptotic index and the lowest bcl-2 levels. As Maiuri et
al. used Bcl-2 inhibitor ABT-737 and they found that
Bcl-2 inhibition led to free an autophagy inducer named
beclin-1 [31]. In addition, Zhivotovsky and Orrenius
suggested the cross-talk between cell death modalities
that different signals can cause a shift from autophagy
to apoptosis or apoptosis to autophagy or mixture of
these two cell-death modes[32]. In our previous study
which the combination of IM and chloripramine was
tested in rat-derived glioma-C6 glioma cells, we consid-
ered that autophagy in the IM group may promote
apoptosis [33]. No autophagic vacuoles were observed in
the Nos group. In the combination group, the autopha-
gic vacuoles were rarely seen. The combination group
had the lowest apoptotic index and highest bcl-2 levels.
We can speculate that the combination group couldn’t
inhibit bcl-2 levels and free autophagy inducer. Even-
tually, the autophagy couldn’t occur and undergo
apoptosis.
Broad success of MK inhibitors in preclinical studies
make them highlighting targets in treating cancer [34].
IM induced the highest decrease and Nos led to mild
decrease in MK levels, however the combination group
increased MK levels at the end of the 72
nd hr. The
antagonist effect of the combination group was related
to high MK levels. In addition, Hu et al. reported that
the MK gene may take part in multi drug resistance
[35]. They showed that a powerful drug efflux ability
Figure 9 Transmission electron microscopic views of T98G GBM spheroids at the 24
th hr. (A) The control group (original magnification,
×7500). (B) The IM group (original magnification, ×7500; original magnification of small micrograph ×7500). (C) The Nos group (original
magnification, ×10,000).(D) The combination group (original magnification of ×7500; original magnification of small micrograph ×10,000). n,
nucleus; mi, mitochondria; lt, lytic cytoplasm; av, autophagic vacuole, v, vacuole; (®): disruptions of cell junctions; mv, microvillus; lp, lipid
droplets; er, endoplasmic reticulum.
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Page 9 of 11correlated with high MK gene expression in lymphoblas-
tic leukemia cells. In the present study In the present
study, the combination group had the highest MK level
but the lowest MRP-1 levels and lower P-gp levels.
Thus, we can conclude that drug efflux ability was not
correlated with MK levels in this experiment.
We also want to discuss the relationship between
autophagy and MK. In the IM group we concluded
above that autophagy was part of IM-induced cytotoxi-
city. Lowest MK levels were detected in the IM group,
however the highest MK level were detected in the com-
bination group. Consequently, we can speculate that MK
can be modulator for cell death or cell survival. T98G
control cells expresses MK highly and they are ancho-
rage independent. We can also propose that T98G GBM
cells escape from an anchorage dependent cell death
anoikis because of the high MK activity. The underlying
mechanism of this relationship was under investigation.
Conclusions
The combination of Nos with IM showed antagonist
effect in T98G human GBM cells in vitro. This antago-
nist effect was correlated highly with MK levels. The
effects of NOS on MRP-1, MK and TKR levels were
firstly demonstrated in our report. In addition, we pro-
posed that MK is one of the modulator in the switch of
autophagy to cell death or survival/resistance.
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